Compare · CNMD vs NUWE
CNMD vs NUWE
Side-by-side comparison of CONMED Corporation (CNMD) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and NUWE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CNMD is the larger of the two at $1.16B, about 371.6x NUWE ($3.1M).
- Over the past year, CNMD is down 24.5% and NUWE is down 97.2% - CNMD leads by 72.8 points.
- NUWE has been more active in the news (7 items in the past 4 weeks vs 2 for CNMD).
- CNMD has more recent analyst coverage (14 ratings vs 1 for NUWE).
- Company
- CONMED Corporation
- Nuwellis Inc.
- Price
- $38.41+2.52%
- $1.16-0.43%
- Market cap
- $1.16B
- $3.1M
- 1M return
- +3.74%
- +4.50%
- 1Y return
- -24.48%
- -97.24%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- News (4w)
- 2
- 7
- Recent ratings
- 14
- 1
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest CNMD
- SEC Form DEFA14A filed by CONMED Corporation
- SEC Form DEF 14A filed by CONMED Corporation
- SEC Form 4 filed by Beyer Pat
- CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by CONMED Corporation
- Amendment: SEC Form 4 filed by Lalomia Brent
- Amendment: SEC Form 4 filed by Schabacker Matthew
- Amendment: SEC Form 4 filed by Foust Hollie K
- Amendment: SEC Form 4 filed by Ferrell John D.
- Amendment: SEC Form 4 filed by Shagory Peter K
Latest NUWE
- Nuwellis Inc. filed SEC Form 8-K: Other Events
- Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
- Nuwellis Announces Aquadex Software Update
- Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum
- Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
- Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory
- SEC Form DEFA14A filed by Nuwellis Inc.
- SEC Form DEF 14A filed by Nuwellis Inc.
- Amendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone